Table 4.

Comparison of severe AEs between the two groups.

Type of AEs	All (N = 95)	ICIs (n = 53)	ICIs + Antiangiogenic agents (n = 42)	p
All severe AEs	22 (23.4%)	10 (18.9%)	12 (29.3%)	.238
Dermatitis	5 (5.3%)	2 (3.8%)	3 (7.3%)	.448
Embolism	3 (3.2%)	1 (1.9%)	2 (4.9%)	.413
Hemoptysis	4 (4.3%)	1 (1.9%)	3 (7.3%)	.196
Diarrhoea	2 (2.1%)	0 (0.0%)	2 (4.9%)	.104
Hypohepatia	1 (1.1%)	1 (1.9%)	0 (0.0%)	.377
Bone marrow suppression	3 (3.2%)	1 (1.9%)	2 (4.9%)	.413
Immune pneumonia	2 (2.1%)	1 (1.9%)	1 (2.4%)	.854
Immune myocarditis	1 (1.1%)	0 (0.0%)	1 (2.4%)	.253
Immune-related myositis	1 (1.1%)	1 (1.9%)	0 (0.0%)	.377
Immune-related ophthalmia	1 (1.1%)	1 (1.9%)	0 (0.0%)	.377
Hypothyroidism	2 (2.1%)	2 (3.8%)	0 (0.0%)	.209

AEs, adverse events; ICIs, immune checkpoint inhibitors.